AstraZeneca PLC and Ionis Pharmaceuticals, Inc. obtained US Food and Drug Administration approval on 21 December for Wainua (eplontersen) in the treatment of adults with hereditary transthyretin mediated amyloidosis (ATTR) with polyneuropathy (ATTR-PN). Phase III data in ATTR cardiomyopathy are not expected until 2025, but AstraZeneca sees Wainua as an important addition to its cardiovascular disease portfolio, while Ionis views the drug as a big first step for its commercial organization.
AstraZeneca, Ionis Win A Key US FDA Approval With Wainua For ATTR Polyneuropathy
Drug Launches In January Under Co-Commercialization Deal
AstraZeneca adds an important product to its cardiovascular, renal and metabolism (CVRM) portfolio and Ionis gains the first drug it will commercialize as it prepares for its first wholly owned launch.
